Metavention
Minneapolis
Founded: 2012
Metavention could potentially change the game when it comes to the treatment of type 2 diabetes. The solution is transcatheter-based metabolic neuromodulation therapy.
The goal is to “provide improved control of elevated glucose, in a single minimally invasive procedure,” according to CEO Todd Berg.
The company in January closed a $65 million Series C round, with funding from New Enterprise Associates, Sanderling Ventures and others. The money is going toward optimizing Metavention’s neuromodulation therapy as the company prepares for a Phase II trial in the U.S.
The goal is to “provide improved control of elevated glucose, in a single minimally invasive procedure,” according to CEO Todd Berg.
–Chris Newmarker, Managing Editor